3 results
Primary objective:To establish the safety and toxicity profile of treatment with Ho-166-PLLA-MS.Secondary objectives:• To evaluate tumor response. • To evaluate patient dosimetry. • To evaluate performance status.• To evaluate Quality of Life (QOL…
The objective of this pivotal study is to assess the PK and PD as well as safety and tolerability of RP103 compared to Cystagon® in patients with nephropathic cystinosis. Results of this Phase 3 study will be used to support the registration…
The primary objective of this study is to determine if left atrial appendage closure with the WATCHMAN FLX device is a reasonablealternative to non-vitamin K oral anticoagulants (NOACs) in patients with non-valvular atrial fibrillation.